International Urology Experts Present on Cxbladder

Company Announcement
20 May 2019

International urology experts present on Cxbladder


Pacific Edge Limited (NZX: PEB) is hosting an event today in Auckland, with two internationally renowned urologists
presenting on the performance and commercial use of Cxbladder in their USA and New Zealand clinical settings
respectively. Videos of their presentations can be viewed on Pacific Edge’s website at:
https://www.cxbladder.com/nz/clinician-information/resources/

Dr Sia Daneshmand: Associate Professor of Urology and Director of Urologic Oncology, Keck Medical Centre -
University of Southern California. Dr Daneshmand recently presented at the prestigious South East Asian Urofair
2019 conference in Singapore, on Urine Biomarkers and the Detection of Urothelial Carcinoma.

Dr Madhusudan Koya: Clinical Director of Urology at Waitemata DHB and President of the New Zealand section of
the Urological Society of Australia and New Zealand. Dr Koya also presented at Urofair 2019 and will be discussing
the real world use of Cxbladder and its clinical utility in New Zealand.

Dr Daneshmand’s and Dr Koya’s presentations demonstrate the accumulated clinical evidence underpinning the
adoption of Cxbladder, its commercial use and the benefits for patients, physicians, healthcare funders and
providers alike.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its non-invasive, simple
to use and accurate Cxbladder tests enable the detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder provides actionable results and better detection and management of urothelial cancer. The company
is developing and commercialising its range of Cxbladder tests globally and has two wholly owned accredited laboratories in
New Zealand and the USA. The company’s products have been tested and validated in multiple international clinical studies.

ABOUT Cxbladder Triage
Cxbladder Triage accurately identifies patients with haematuria who have a low probability of bladder cancer and may not
require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary
evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients
who have a low probability of having urothelial cancer.

ABOUT Cxbladder Detect
Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an
effective adjunct to cystoscopy. Is often used in conjunction with Cxbladder Triage to provide greater rule-out and resolution
of patients who have UC.

Company Announcement
20 May 2019


ABOUT Cxbladder Monitor
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
cancer. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.